Structure-activity relationships of multidrug resistance reversers

被引:146
作者
Wiese, M [1 ]
Pajeva, IK
机构
[1] Univ Bonn, Inst Pharmaceut, D-53121 Bonn, Germany
[2] Bulgarian Acad Sci, Ctr Biomed Engn, BU-1113 Sofia, Bulgaria
关键词
D O I
10.2174/0929867013373138
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multidrug resistance, MDR, is a major obstacle in the chemotherapeutic treatment of cancer. MDR can be reversed by drugs that vary widely in their chemical structure and main biological action. Many efforts are directed to find out the relationships between the structure and MDR reversal effect of these drugs. In this review we try to summarize the results of a variety of studies on identification of. structure-activity relationships, SARs, and quantitative SARs, QSARs, of different MDR reversing drugs. As any reasonable (Q)SAR study relies on a real or putative presentation about the mechanism of action of the studied compounds, the most significant MDR mechanisms revealed till now are shortly discussed. Special attention is paid to P-glycoprotein, P-gp, related MDR as the most experimentally and clinically tested form of drug resistance. The currently proposed models of P-gp functioning and mechanisms of MDR modulation are presented. Problems that can arise in (Q)SARs studies are discussed in advance to allow the reader to judge on possible pitfalls. The physicochemical and structural properties of MDR modulators as found by different research groups are commented and summarized. From the discussed studies it can be concluded that the careful selection of relevant structural and biological data processed with appropriate QSAR and especially SD-QSAR methods, is a promising approach to structure-activity studies of MDR reversers.
引用
收藏
页码:685 / 713
页数:29
相关论文
共 123 条
[1]  
Abraham DJ., 1993, 3D QSAR in Drug Design, Theory, Methods and Applications, P506
[2]  
*ADV CHEM DEV INC, 1995, ACD LOGP 1 0
[3]  
AFTAB DT, 1991, MOL PHARMACOL, V40, P798
[4]  
Ahkmed N., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P339
[5]   2,3-dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines:: Synthesis, biological evaluation, and structure-activity relationships [J].
Antonini, I ;
Polucci, P ;
Kelland, LR ;
Menta, E ;
Pescalli, N ;
Martelli, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (14) :2535-2541
[6]   Kinetic analysis of the mechanism of action of the multidrug transporter [J].
Ashida, H ;
Oonishi, T ;
Uyesaka, N .
JOURNAL OF THEORETICAL BIOLOGY, 1998, 195 (02) :219-232
[7]   Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein [J].
Ayesh, S ;
Shao, YM ;
Stein, WD .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1316 (01) :8-18
[8]  
Ayesh S, 1997, RECEPTOR CHANNEL, V5, P175
[9]  
Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.2307/3433698
[10]  
BARONE LR, 1996, MULTIDRUG RESISTANCE, P151